Organon & Co. (OGN) To Go Ex-Dividend on February 24th

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Thursday, February 13th, Wall Street Journal reports. Shareholders of record on Monday, February 24th will be given a dividend of 0.28 per share on Thursday, March 13th. This represents a $1.12 dividend on an annualized basis and a yield of 7.24%. The ex-dividend date of this dividend is Monday, February 24th.

Organon & Co. has raised its dividend by an average of 26.0% annually over the last three years. Organon & Co. has a dividend payout ratio of 26.7% meaning its dividend is sufficiently covered by earnings. Research analysts expect Organon & Co. to earn $3.74 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 29.9%.

Organon & Co. Stock Down 1.4 %

OGN opened at $15.47 on Friday. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The firm’s fifty day moving average price is $15.36 and its two-hundred day moving average price is $17.28. The company has a market capitalization of $3.98 billion, a P/E ratio of 4.64, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. On average, analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on OGN. Barclays decreased their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Morgan Stanley cut their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Organon & Co. has a consensus rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.